NUMELVI™ (atinvicitinib tablets) is a prescription medication for the control of itch associated with allergic dermatitis in dogs. Numelvi acts fast to relieve itch and deliver the comfort your dog deserves.
Numelvi is given once daily with food at or around mealtime and is labeled for use in dogs and puppies 6 months of age and older. Discover NUMELVI™ (atinvicitinib tablets) for dogs. Available by prescription only.
NUMELVI is not for use in dogs less than 6 months of age or those with serious infections. NUMELVI may increase susceptibility to opportunistic infections, including demodicosis and interdigital furunculosis. Consider the risks and benefits of treatment prior to initiating NUMELVI in dogs with a history of recurrent demodicosis. NUMELVI is a JAK inhibitor. New neoplastic conditions (benign and malignant) have been reported in dogs treated with other JAK inhibitors. The effectiveness and safety of NUMELVI have not been evaluated in a field study beyond 28 days. The safe use of NUMELVI has not been evaluated in breeding, pregnant, or lactating dogs, nor in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. For complete safety information, refer to the product label.
* In a canine interleukin-31 (cIL-31)-induced pruritus model. † No clinically relevant drug interactions observed during 28-day field trial in dogs with allergic dermatitis after use with antimicrobials (including topicals), ecto- and endoparasiticides (isoxazolines, milbemycins, avermectins, pyrethrins, and pyrethroids), analgesics, anesthetics, nutritional supplements, topical skin and ear cleansers that did not contain glucocorticoids, as well as medicated shampoos. 1. Kowalski T, Prohaczik A, Locke K, et al. The second-generation Janus kinase inhibitor atinvicitinib significantly reduces pruritus 2-4 hours after dosing dogs in a canine interleukin-31 model. Vet Dermatol. 2026;0:17-18. https://doi.org/10.1111/vde.70046 2. Data on File. Study Summary REF-11196. Merck Animal Health